{"news_desk": "Business", "print_page": "1", "subsection_name": null, "section_name": "Business Day", "byline": {"contributor": "Reed Abelson contributed reporting.", "original": "By ANDREW POLLACK", "person": [{"firstname": "Andrew", "rank": 1, "lastname": "POLLACK", "organization": "", "role": "reported"}]}, "abstract": "Mylan's skyrocketing prices for its anti-allergy drug injector EpiPen spotlights common tactic in drug history, in which companies jack prices in years before generic competitor appears on market, in effort to extract huge profits from brand-name drug.", "type_of_material": "News", "word_count": "1146", "keywords": [{"rank": "1", "value": "Mylan Inc", "is_major": "Y", "name": "organizations"}, {"rank": "3", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Generic Brands and Products", "is_major": "Y", "name": "subject"}, {"rank": "5", "value": "Medical Devices", "is_major": "N", "name": "subject"}, {"rank": "6", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "name": "subject"}, {"rank": "7", "value": "Food and Drug Administration", "is_major": "N", "name": "organizations"}, {"rank": "8", "value": "Sanofi SA", "is_major": "N", "name": "organizations"}, {"rank": "9", "value": "Epinephrine (Drug)", "is_major": "N", "name": "subject"}, {"rank": "10", "value": "Allergies", "is_major": "Y", "name": "subject"}], "lead_paragraph": "Mylan\u2019s price increases for the allergy treatment device highlight a common tactic in the industry: raising prices just before a generic competitor reaches the market.", "pub_date": "2016-08-25T04:00:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "Mylan\u2019s price increases for the allergy treatment device highlight a common tactic in the industry: raising prices just before a generic competitor reaches the market....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/08/25/business/25EPPEN/25EPPEN-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/08/25/business/25EPPEN/25EPPEN-thumbWide.jpg"}, {"height": 399, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "399", "xlarge": "images/2016/08/25/business/25EPPEN/25EPPEN-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/08/25/business/25EPPEN/25EPPEN-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/08/25/business/25EPPEN/25EPPEN-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/08/25/business/25EPPEN/25EPPEN-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/08/25/business/mylan-raised-epipens-price-before-the-expected-arrival-of-a-generic.html", "slideshow_credits": null, "blog": [], "_id": "57be420195d0e021d7982797", "headline": {"main": "Mylan Raised EpiPen\u2019s Price Before the Expected Arrival of a Generic", "print_headline": "Last Shot at EpiPen Profits Ends in a Mylan Monopoly"}}